The U.S. Food and Drug Administration allowed Philip Morris International to market Zyn nicotine pouches as a lower-risk alternative to cigarettes [1, 2].
This decision marks a significant shift in how nicotine products can be advertised in the U.S. By permitting "lower-risk" claims, the agency acknowledges a potential path for smokers to transition to non-combustible products, though it opens a debate over the long-term safety of nicotine pouches.
The FDA announced the decision on Jan. 23, 2026 [2]. The agency said that Zyn's non-combustible nicotine delivery system may present a lower risk of disease compared to smoking traditional cigarettes [1, 2].
Philip Morris International, the manufacturer of Zyn, can now use this designation in its marketing materials to target current smokers. The move is based on the premise that removing the combustion process—the act of burning tobacco—reduces the intake of many carcinogens found in cigarette smoke.
However, the decision has met with pushback from some health experts. Critics said that there is insufficient evidence to definitively claim Zyn is safer than smoking [1]. These experts said that the product still carries nicotine-related risks, and may not be a truly safe alternative for all users [1].
While the FDA has provided the regulatory green light for these claims, the medical community remains divided on the public health impact. Some said that the product is a positive tool for harm reduction, while others said that the potential for addiction and unknown long-term effects of the pouch ingredients outweigh the benefits of avoiding smoke [1].
“The FDA concluded that Zyn’s non‑combustible nicotine delivery may present a lower risk of disease compared with smoking cigarettes.”
This regulatory shift signals a move toward a 'harm reduction' framework by the FDA, prioritizing the reduction of combustible tobacco use over total nicotine abstinence. By allowing companies to claim a product is lower-risk, the government is effectively endorsing a tiered approach to public health, though it risks encouraging nicotine dependency among populations that might otherwise quit entirely.
